Monoclonal Antibodies in Diabetes Diagnosis: Role in Type 1 (Juvenile) Diabetes

Monoclonal antibodies are not used as primary diagnostic tools for type 1 diabetes (T1D). They are research/reagent tools for measuring autoantibodies.

Actual T1D Diagnostic Criteria (ADA)

  • Hyperglycemia: FPG ≥126, or 2-hr PG ≥200 on OGTT, or random PG ≥200 + symptoms, or HbA1c ≥6.5%
  • Autoantibodies (confirm autoimmune etiology):
    • GAD65 (glutamic acid decarboxylase) — most common (70–80%)
    • IA-2 (tyrosine phosphatase) — 60–70%
    • ZnT8 (zinc transporter 8) — 60–80%
    • IAA (insulin autoantibodies) — higher in young children
    • ICA (islet cell antibodies) — immunofluorescence, less used now
  • C-peptide: Low/undetectable (confirms insulin deficiency)
  • Genetic testing: HLA-DR3/DR4-DQ8 (risk stratification); monogenic diabetes genes (MODY) if atypical

How Monoclonal Antibodies Are Used

  • As capture/detection antibodies in commercial autoantibody assays (ELISA, RBA, ECL)
  • Research: Islet isolation, β-cell markers, immunotherapy targets (teplizumab — anti-CD3 mAb delays T1D onset)
  • Not a patient-facing test — clinicians order "GAD65 antibody," not "monoclonal antibody test"

Teplizumab (Tzield)

FDA-approved (2022) anti-CD3 monoclonal antibody for delaying Stage 3 T1D in ≥8 yr olds with Stage 2 (dysglycemia + ≥2 autoantibodies). First disease-modifying therapy.

Diabetes - Related Articles